Gucy2c t cell-antigen couplers and uses thereof
AssigneeTriumvira Immunologics USA, Inc.
InventorsAndreas Bader, Christopher W. Helsen, Philbert Ip, Tania Benatar
Life of this patent
Estimating the term…
Abstract
GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.
Claims29
A Guanylate Cyclase 2C (GUCY2C) T cell-antigen coupler (GUCY2C-TAC) protein, comprising:
- (a) a first polypeptide encoding an antigen-binding domain that binds GUCY2C, wherein:
- i) the GUCY2C antigen-binding domain comprises a heavy chain variable region comprising (a) a CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 204, 210, 216, 222, 228, 234, 240, 246, 252, 258, 264, 270, 276, 282, 288, 294, 300, 306, 312, 318, 324, 330, 336, 342, 348, 354, 393, 399, 405, 411, 417, 423, 429, 435, 441, 447, 453, 459, 522, 525, 528, 531, 534, 537, 540, and 543, (b) a CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 205, 211, 217, 223, 229, 235, 241, 247, 253, 259, 265, 271, 277, 283, 289, 295, 301, 307, 313, 319, 325, 331, 337, 343, 349, 355, 394, 400, 406, 412, 418, 424, 430, 436, 442, 448, 454, 460, 523, 526, 529, 532, 535, 538, 541, and 544, and (c) a CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 206, 212, 218, 224, 230, 236, 242, 248, 254, 260, 266, 272, 278, 284, 290, 296, 302, 308, 314, 320, 326, 332, 338, 344, 350, 356, 395, 401, 407, 413, 419, 425, 431, 437, 443, 449, 455, 461, 524, 527, 530, 533, 536, 539, 542, and 545;
- and a light chain variable region comprising (a) a CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 207, 213, 219, 225, 231, 237, 243, 249, 255, 261, 267, 273, 279, 285, 291, 297, 303, 309, 315, 321, 327, 333, 339, 345, 351, 357, 396, 402, 408, 414, 420, 426, 432, 438, 444, 450, 456 and 462, (b) a CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 208, 214, 220, 226, 232, 238, 244, 250, 256, 262, 268, 274, 280, 286, 292, 298, 304, 310, 316, 322, 328, 334, 340, 346, 352, 358, 397, 403, 409, 415, 421, 427, 433, 439, 445, 451, 457 and 463, and (c) a CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 209, 215, 221, 227, 233, 239, 245, 251, 257, 263, 269, 275, 281, 287, 293, 299, 305, 311, 317, 323, 329, 335, 341, 347, 353, 359, 398, 404, 410, 416, 422, 428, 434, 440, 446, 452, 458 and 464;
- or
- ii) the GUCY2C antigen-binding domain is a nanobody and comprises (a) a VHH CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 360, 363, 366, 369, 372, 375, 378, 381, 384, 387, and 390:
- (b) a VHH CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 361, 364, 367, 370, 373, 376, 379, 382, 385, 388, and 391;
- and (c) a VHH CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 362, 365, 368, 371, 374, 377, 380, 383, 386, 389, and 392:
- (b) a second polypeptide encoding an antigen-binding domain that binds a protein associated with a TCR complex;
- and
- (c) a third polypeptide encoding a TCR co-receptor cytosolic domain and transmembrane domain;
- wherein components encoded by (a), components encoded by (b), and components encoded by (c) are fused directly to each other, or joined by at least one linker.
2-5. (canceled)
-9. (canceled)
-15. (canceled)
-30. (canceled)
-33. (canceled)
-38. (canceled)
-47. (canceled)
A GUCY2C TAC protein comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NOs:
- 465-513, 546-590, or 686.
(canceled)
-53. (canceled)
Dependencies are inferred from the claim text.